Baseline clinicopathological characteristics of the cohort
| Characteristics | Cases (n = 604) | % |
| Age (years) | ||
| ≤ 50 | 309 | 51.16 |
| > 50 | 295 | 48.84 |
| BC family history | ||
| No | 481 | 79.64 |
| Yes | 123 | 20.36 |
| BMI | ||
| < 25 | 457 | 75.66 |
| ≥ 25 | 126 | 20.86 |
| Unknown | 21 | 3.48 |
| Discharge | ||
| No | 520 | 86.09 |
| Yes | 84 | 13.91 |
| Tumor size on ultrasonography | ||
| ≤ 2 cm | 229 | 37.91 |
| > 2 cm | 331 | 54.80 |
| Unknown | 44 | 7.28 |
| Calcification on mammography | ||
| Yes | 363 | 60.10 |
| No | 79 | 13.08 |
| Unknown | 162 | 26.82 |
| BI-RADS | ||
| 3 | 6 | 0.99 |
| 4A | 27 | 4.47 |
| 4B | 115 | 19.04 |
| 4C | 275 | 45.53 |
| 5 | 163 | 26.99 |
| Unknown | 18 | 2.98 |
| ER | ||
| Negative | 254 | 42.05 |
| Positive | 340 | 56.29 |
| Unknown | 10 | 1.66 |
| HER2 | ||
| Negative | 281 | 46.52 |
| Positive | 313 | 51.82 |
| Unknown | 10 | 1.66 |
| Ki67 | ||
| ≤ 14% | 136 | 22.51 |
| > 14% | 418 | 69.20 |
| Unknown | 50 | 8.29 |
| Surgical methods | ||
| Mastectomy | 548 | 90.73 |
| BCS | 56 | 9.27 |
| Axillary evaluation | ||
| SLNB | 513 | 84.93 |
| ALND | 91 | 15.07 |
| Upstaging group | ||
| DCIS | 290 | 48.01 |
| DCISM | 121 | 20.03 |
| IBC | 193 | 31.95 |
BC, breast cancer; BMI, body mass index; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; BCS, breast conserving surgery; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection; DCIS, ductal carcinoma in situ; DCISM, ductal carcinoma in situ with microinvasion; IBC, invasive breast cancer.